A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Trial Profile

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Amlodipine/chlortalidone/telmisartan (Primary) ; Amlodipine/telmisartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Yuhan
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2016.
    • 16 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top